Regulus Therapeutics Inc. (NASDAQ:RGLS) Receives $11.75 Consensus Target Price from Brokerages

Regulus Therapeutics Inc. (NASDAQ:RGLS) has earned a consensus recommendation of “Moderate Buy” from the five analysts that are covering the firm, Marketbeat Ratings reports. One analyst has rated the stock with a hold recommendation and four have assigned a buy recommendation to the company. The average 12 month price objective among brokerages that have issued ratings on the stock in the last year is $11.75.

A number of research analysts have commented on the company. StockNews.com initiated coverage on Regulus Therapeutics in a report on Tuesday, April 16th. They set a “sell” rating on the stock. Canaccord Genuity Group raised their price objective on Regulus Therapeutics from $11.00 to $28.00 and gave the stock a “buy” rating in a research note on Tuesday, June 25th. Finally, HC Wainwright reiterated a “buy” rating and set a $10.00 target price on shares of Regulus Therapeutics in a research note on Tuesday, July 16th.

Hedge Funds Weigh In On Regulus Therapeutics

Several institutional investors have recently made changes to their positions in RGLS. Victory Capital Management Inc. boosted its position in Regulus Therapeutics by 16.5% during the 4th quarter. Victory Capital Management Inc. now owns 271,736 shares of the biopharmaceutical company’s stock valued at $348,000 after purchasing an additional 38,529 shares during the period. Opaleye Management Inc. bought a new stake in Regulus Therapeutics in the first quarter valued at $490,000. Vanguard Group Inc. boosted its holdings in shares of Regulus Therapeutics by 158.4% during the first quarter. Vanguard Group Inc. now owns 740,215 shares of the biopharmaceutical company’s stock valued at $2,132,000 after acquiring an additional 453,784 shares during the period. CVI Holdings LLC acquired a new position in shares of Regulus Therapeutics during the first quarter valued at $4,050,000. Finally, Vivo Capital LLC bought a new position in shares of Regulus Therapeutics during the first quarter worth about $14,400,000. 92.38% of the stock is owned by institutional investors.

Regulus Therapeutics Trading Up 0.6 %

Shares of NASDAQ:RGLS opened at $1.76 on Friday. The firm has a market cap of $115.23 million, a PE ratio of -1.21 and a beta of 1.62. The company has a fifty day simple moving average of $2.03 and a 200 day simple moving average of $1.97. Regulus Therapeutics has a 12-month low of $1.08 and a 12-month high of $3.79.

Regulus Therapeutics (NASDAQ:RGLS) last released its earnings results on Thursday, May 9th. The biopharmaceutical company reported ($0.29) earnings per share for the quarter, missing the consensus estimate of ($0.15) by ($0.14). As a group, equities research analysts forecast that Regulus Therapeutics will post -0.59 EPS for the current fiscal year.

About Regulus Therapeutics

Regulus Therapeutics Inc, a clinical-stage biopharmaceutical company, focuses on discovery and development of drugs that targets microRNAs to treat a range of diseases in the United States. Its product candidates include RGLS8429, an anti-miR next generation oligonucleotide targeting miR-17, which is in Phase 1b clinical trial for the treatment of autosomal dominant polycystic kidney disease.